Grown Rogue International (GRUSF) Capital Expenditures Growth (1y) (2019 - 2026)
Grown Rogue International (GRUSF) Capital Expenditures Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Grown Rogue International | 110.47 Mn | 98.93 Mn | 5.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 942.27% |
| Dec 31, 2025 | -16.65% |
| Sep 30, 2025 | 16.65% |
| Jun 30, 2025 | -235.68% |
| Mar 31, 2025 | 181.24% |
| Dec 31, 2024 | 1,000,503,556.29% |
| Jan 31, 2023 | 93.67% |
| Jan 31, 2022 | -461.34% |
| Oct 31, 2021 | -1,283.88% |
| Jul 31, 2021 | -1,152.22% |
| Apr 30, 2021 | 49.32% |
| Jan 31, 2021 | 3,411.84% |
| Oct 31, 2020 | -90.74% |
| Jul 31, 2020 | 615.27% |
| Apr 30, 2020 | 336.88% |
| Jan 31, 2020 | 105.73% |
| Oct 31, 2019 | -74.34% |
| Jul 31, 2019 | -134.51% |
| Apr 30, 2019 | 12.30% |
| Jan 31, 2019 | 89.02% |